Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

NCT03150056 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

73

Enrollment

INDUSTRY

Sponsor class

Stopped This study has been terminated due to meeting protocol defined futility.

Conditions

Solid Tumours

Interventions

DRUG: GSK525762
DRUG: Abiraterone
DRUG: Enzalutamide
DRUG: Prednisone

Sponsor

GlaxoSmithKline